The presence of Vγ9Vδ2 T cells, in many different malignancies, is correlated with a favorable prognosis for survival. Vγ9Vδ2 T cells sense stress signals in tumor cells to induce tumor cell destruction.
LAVA’s bispecific antibodies target and engage Vγ9Vδ2 T cells. The bispecific antibodies enhance the killing potential of Vγ9Vδ2 T cells while leaving the natural mechanism of action intact. Presentation of tumor-associated antigens by Vγ9Vδ2 T cells to ⍺β T cells could lead to long lasting responses.
Visit our process page to see how our award winning animations get created.
1275 Shiloh Road, Suite 3130 Kennesaw, GA 30144 | Toll-free: 800-333-0753 | Phone: 770-805-0460 | Email: Nucleus Medical Media
©2021 Nucleus Medical Media. All rights reserved.